-
European Journal of Neurology Jan 2017
Topics: Biomarkers; Disease Progression; Humans; Multiple Sclerosis
PubMed: 27699927
DOI: 10.1111/ene.13170 -
Journal of the American College of... Feb 2022
Topics: Disease Progression; Humans; Pulmonary Disease, Chronic Obstructive
PubMed: 35177202
DOI: 10.1016/j.jacc.2021.12.006 -
American Journal of Respiratory and... Nov 2017
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Vital Capacity
PubMed: 28700255
DOI: 10.1164/rccm.201706-1246ED -
Clinical Journal of the American... Mar 2019
Topics: Disease Progression; Humans; Hyperkalemia; Potassium; Potassium, Dietary; Renal Insufficiency, Chronic
PubMed: 30765535
DOI: 10.2215/CJN.01020119 -
Expert Review of Neurotherapeutics Aug 2016There is consensus that exercise represents a behavioral approach for the restoration of function and management of symptoms among persons with multiple sclerosis (MS).... (Review)
Review
INTRODUCTION
There is consensus that exercise represents a behavioral approach for the restoration of function and management of symptoms among persons with multiple sclerosis (MS). The current paper provides a review on the topic of exercise and physical activity as MS-disease modifying treatments.
AREAS COVERED
Firstly, metrics for evaluating disease modification and progression in MS are described. Secondly, evidence for exercise as a MS-disease modifying therapy based on individual studies, literature reviews, and meta-analyses is summarized. Finally, the paper focuses on major limitations of the existing body of research. Expert commentary: Exercise and physical activity have been associated with reduced relapse rate, mobility disability and its progression, and lesion volume, and improved neuroperformance, particularly walking outcomes. This evidence provides a positive, yet preliminary, picture for exercise having possible effects on markers of disease modification and progression in MS.
Topics: Disabled Persons; Disease Progression; Exercise; Exercise Therapy; Humans; Multiple Sclerosis
PubMed: 27219279
DOI: 10.1080/14737175.2016.1193008 -
Amyotrophic Lateral Sclerosis &... Feb 2024Decrease in the revised ALS Functional Rating Scale (ALSFRS-R) score is currently the most widely used measure of disease progression. However, it does not sufficiently...
BACKGROUND, OBJECTIVES
Decrease in the revised ALS Functional Rating Scale (ALSFRS-R) score is currently the most widely used measure of disease progression. However, it does not sufficiently encompass the heterogeneity of ALS. We describe a measure of variability in ALSFRS-R scores and demonstrate its utility in disease characterization.
METHODS
We used 5030 ALS clinical trial patients from the Pooled Resource Open-Access ALS Clinical Trials database to calculate variability in disease progression employing a novel measure and correlated variability with disease span. We characterized the more and less variable populations and designed a machine learning model that used clinical, laboratory and demographic data to predict class of variability. The model was validated with a holdout clinical trial dataset of 84 ALS patients (NCT00818389).
RESULTS
Greater variability in disease progression was indicative of longer disease span on the patient-level. The machine learning model was able to predict class of variability with accuracy of 60.1-72.7% across different time periods and yielded a set of predictors based on clinical, laboratory and demographic data. A reduced set of 16 predictors and the holdout dataset yielded similar accuracy.
DISCUSSION
This measure of variability is a significant determinant of disease span for fast-progressing patients. The predictors identified may shed light on pathophysiology of variability, with greater variability in fast-progressing patients possibly indicative of greater compensatory reinnervation and longer disease span. Increasing variability alongside decreasing rate of disease progression could be a future aim of trials for faster-progressing patients.
Topics: Humans; Amyotrophic Lateral Sclerosis; Disease Progression
PubMed: 37794802
DOI: 10.1080/21678421.2023.2260838 -
Clinical Gastroenterology and... Feb 2020
Topics: Aspirin; Disease Progression; Fibrosis; Humans; Non-alcoholic Fatty Liver Disease
PubMed: 31352095
DOI: 10.1016/j.cgh.2019.07.041 -
The Lancet. Neurology Sep 2017
Topics: Disease Progression; Humans; Huntington Disease
PubMed: 28642122
DOI: 10.1016/S1474-4422(17)30179-5 -
American Journal of Ophthalmology Feb 2018
Topics: Disease Progression; Glaucoma; Humans; Risk Factors
PubMed: 29221821
DOI: 10.1016/j.ajo.2017.11.007 -
Clinical Gastroenterology and... Mar 2018
Topics: Child; Disease Progression; Fibrosis; Humans; Liver; Non-alcoholic Fatty Liver Disease
PubMed: 29199148
DOI: 10.1016/j.cgh.2017.11.040